These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 28585477)

  • 21. Access to generic antiretrovirals: inequality, intellectual property law, and international trade agreements.
    Castro A; Westerhaus M
    Cad Saude Publica; 2007; 23 Suppl 1():S85-96. PubMed ID: 17308722
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Patent implications in the pharmaceutical industry: Are static high prices leading to dynamic innovations?
    Pandey E; Paul SB
    Int J Risk Saf Med; 2019; 30(3):179-192. PubMed ID: 31450515
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Understanding the trends in international agreements on pricing and reimbursement for newly marketed medicines and their implications for access to medicines: a computational text analysis.
    Son KB
    Global Health; 2020 Oct; 16(1):98. PubMed ID: 33054820
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Addressing legal and political barriers to global pharmaceutical access: options for remedying the impact of the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) and the imposition of TRIPS-plus standards.
    Cohen-Kohler JC; Forman L; Lipkus N
    Health Econ Policy Law; 2008 Jul; 3(Pt 3):229-56. PubMed ID: 18634618
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Affordability versus innovation: Is compulsory licensing the solution?
    Pandey E; Paul SB
    Int J Risk Saf Med; 2019; 30(4):233-247. PubMed ID: 31658067
    [TBL] [Abstract][Full Text] [Related]  

  • 26. WTO approves TRIPS amendment on importing under compulsory licensing.
    Herget G
    HIV AIDS Policy Law Rev; 2006 Apr; 11(1):23-4. PubMed ID: 16805011
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Trans-Pacific Partnership and pharmaceutical innovation.
    Freeman RA
    Res Social Adm Pharm; 2016; 12(4):633-7. PubMed ID: 26803645
    [TBL] [Abstract][Full Text] [Related]  

  • 28. TRIPS-plus and access to medicines in China.
    Chen J; Nie X; Yao P; Shi L
    J Public Health Policy; 2013 May; 34(2):226-38. PubMed ID: 23552834
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Managing the effect of TRIPS on availability of priority vaccines.
    Milstien J; Kaddar M
    Bull World Health Organ; 2006 May; 84(5):360-5. PubMed ID: 16710544
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Canada and access to medicines in developing countries: intellectual property rights first.
    Lexchin J
    Global Health; 2013 Sep; 9():42. PubMed ID: 24007595
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Potential conflict between TRIPS and GATT concerning parallel importation of drugs and possible solution to prevent undesirable market segmentation.
    Lo CF
    Food Drug Law J; 2011; 66(1):73-83, ii. PubMed ID: 24505847
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Affordable antiretroviral drugs for the under-served markets: how to expand equitable access against the backdrop of challenging scenarios?
    Dionisio D; Cao Y; Hongzhou L; Kraisintu K; Messeri D
    Curr HIV Res; 2006 Jan; 4(1):3-20. PubMed ID: 16454707
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Defending access to medicines in regional trade agreements: lessons from the Regional Comprehensive Economic Partnership - a qualitative study of policy actors' views.
    Townsend B
    Global Health; 2021 Jul; 17(1):78. PubMed ID: 34238347
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The right to health and medicines: the case of recent multilateral negotiations on public health, innovation and intellectual property.
    Velasquez G
    Dev World Bioeth; 2014 Aug; 14(2):67-74. PubMed ID: 24813066
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Trans Pacific Partnership Agreement and access to HIV treatment in Vietnam.
    Moir HVJ; Tenni B; Gleeson D; Lopert R
    Glob Public Health; 2018 Apr; 13(4):400-413. PubMed ID: 27841097
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact on access to medicines from TRIPS-Plus: a case study of Thai-US FTA.
    Kessomboon N; Limpananont J; Kulsomboon V; Maleewong U; Eksaengsri A; Paothong P
    Southeast Asian J Trop Med Public Health; 2010 May; 41(3):667-77. PubMed ID: 20578557
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Access to medicines and domestic compulsory licensing: learning from Canada and Thailand.
    Kuek V; Phillips K; Kohler JC
    Glob Public Health; 2011; 6(2):111-24. PubMed ID: 20234967
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A proposal for measuring the degree of public health-sensitivity of patent legislation in the context of the WTO TRIPS Agreement.
    Chaves GC; Oliveira MA
    Bull World Health Organ; 2007 Jan; 85(1):49-56. PubMed ID: 17242758
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Implications of international law for the treatment of cancer: the Single Convention on Narcotic Drugs and the TRIPS Agreement.
    Liberman J
    Public Health; 2011 Dec; 125(12):840-846. PubMed ID: 22054908
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Trade agreements and the risks for the nursing workforce, nursing practice and public health: A scoping review.
    Kidgell D; Hills D; Griffiths D; Endacott R
    Int J Nurs Stud; 2020 Sep; 109():103676. PubMed ID: 32603925
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.